新闻 August 02, 2021

Alvogen Pharma US’s $160 Million Incremental Term Loan

Shearman & Sterling advised Jefferies Finance, as administrative agent and lender, on a $160 million incremental amendment to Alvogen Pharma US’s existing $930 million secured term loan facility, the proceeds of which were used to refinance and extend the maturity of a portion of the existing term loans.

Alvogen, a pharmaceutical company, develops, manufactures and sells the generic, brand, over the counter and bio similar products for patients worldwide. It offers molecules for the treatment of conditions in the areas of oncology, cardiology, respiratory, neurology and gastroenterology. The company also provides contract manufacturing and research services. Alvogen was incorporated in 2008 and is based in Morristown, New Jersey with manufacturing and development facilities in the United States, Romania, Korea and Taiwan. Alvogen operates as a subsidiary of Alvogen Lux Holdings.

The Shearman & Sterling team below included associate Gina Eum (NY-Finance).

The Team